deltatrials
Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT03136263

Oxytocin and Cognitive Control in Adult ADHD

Effects of Oxytocin on Cognitive Control in Adults With Attention Deficit/Hyperactivity Disorder

Sponsor: Massachusetts General Hospital

Conditions Attention Deficit/Hyperactivity Disorder
Interventions Oxytocin nasal spray Placebo nasal spray
Updated 18 times since 2017 Last updated: May 1, 2024 Started: Dec 14, 2017 Primary completion: Nov 5, 2020 Completion: Nov 5, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Attention Deficit/Hyperactivity Disorder and is currently completed. Massachusetts General Hospital leads this study, which shows 18 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jun 2017 – ~Nov 2017 · 5 months · monthly snapshot~Nov 2017 – ~Jan 2018 · 2 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Apr 2019 · 6 months · monthly snapshot~Apr 2019 – ~Sep 2019 · 5 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshot~Jul 2020 – ~Oct 2020 · 3 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Dec 2021 · 8 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jun 2024 · 18 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed EARLY_PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed EARLY_PHASE1

  3. Jun 2024 — Jul 2024 [monthly]

    Completed EARLY_PHASE1

  4. Dec 2022 — Jun 2024 [monthly]

    Completed EARLY_PHASE1

  5. Dec 2021 — Dec 2022 [monthly]

    Completed EARLY_PHASE1

▶ Show 13 earlier versions

  1. Apr 2021 — Dec 2021 [monthly]

    Completed EARLY_PHASE1

    Status: Recruiting → Completed

  2. Jan 2021 — Apr 2021 [monthly]

    Recruiting EARLY_PHASE1

  3. Oct 2020 — Jan 2021 [monthly]

    Recruiting EARLY_PHASE1

  4. Jul 2020 — Oct 2020 [monthly]

    Recruiting EARLY_PHASE1

  5. Mar 2020 — Jul 2020 [monthly]

    Recruiting EARLY_PHASE1

  6. Oct 2019 — Mar 2020 [monthly]

    Recruiting EARLY_PHASE1

  7. Sep 2019 — Oct 2019 [monthly]

    Recruiting EARLY_PHASE1

  8. Apr 2019 — Sep 2019 [monthly]

    Recruiting EARLY_PHASE1

  9. Oct 2018 — Apr 2019 [monthly]

    Recruiting EARLY_PHASE1

  10. Jun 2018 — Oct 2018 [monthly]

    Recruiting EARLY_PHASE1

  11. Jan 2018 — Jun 2018 [monthly]

    Recruiting EARLY_PHASE1

  12. Nov 2017 — Jan 2018 [monthly]

    Recruiting EARLY_PHASE1

    Status: Not Yet Recruiting → Recruiting

  13. Jun 2017 — Nov 2017 [monthly]

    Not Yet Recruiting EARLY_PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Massachusetts General Hospital
Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations